Lyme Disease Testing Market Report 2025

The lyme disease testing market size has grown strongly in recent years. It will grow from $9.77 billion in 2024 to $10.68 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth during the historic period can be attributed to the rising demand for early disease diagnosis, increased accessibility to advanced diagnostic technologies, a growing tick population driven by climate change, enhanced government funding for the control of vector-borne diseases, and the expansion of healthcare infrastructure in rural and endemic regions.

The lyme disease testing market size is expected to see strong growth in the next few years. It will grow to $15.11 billion in 2029 at a compound annual growth rate (CAGR) of 9.1%. The growth during the forecast period can be attributed to the rising travel to Lyme-endemic areas, increased utilization of multiplex diagnostic technologies, a surge in outdoor recreational activities, growing demand for at-home testing kits, and heightened concerns about co-infections with other tick-borne illnesses. Key trends expected in the forecast period include progress in molecular diagnostic methods, advancements in biomarker discovery, technological innovations in point-of-care testing devices, developments in lab-on-a-chip (microfluidic) platforms, and improvements in immunoassay technologies.

The increasing prevalence of tick-borne illnesses is expected to drive the growth of the Lyme disease testing market. Tick-borne illnesses are diseases transmitted to humans through bites from infected ticks, which are small parasites commonly found in grassy, wooded, or rural areas. The demand for treatments and testing related to tick-borne illnesses is rising due to the expanding geographic distribution of ticks, largely influenced by climate change, resulting in greater exposure and infection rates. Since ticks are the primary vectors for Lyme disease, the increase in these illnesses highlights the need for early detection and accurate diagnosis. For example, in July 2024, the Centers for Disease Control and Prevention (CDC), a US-based federal public health agency, reported 71,346 cases of tick-borne diseases in 2022 - up from 36,177 cases in 2021. As a result, the growing number of tick-borne illness cases is fueling the demand for Lyme disease testing.

Companies in the Lyme disease testing market are emphasizing technological innovations in diagnostic tools to improve test accuracy, decrease turnaround times, and support early-stage disease detection. These diagnostic tools include devices, kits, and technologies designed to identify the presence of Lyme disease by detecting antibodies, antigens, or genetic material associated with Borrelia burgdorferi, the bacteria responsible for the disease. For instance, in August 2024, EpitogenX Ltd., a UK-based biotechnology company, launched a new Lyme Disease Diagnostic Kit. This ELISA-based assay was developed using the company’s proprietary EpitoGen platform and includes approximately 120 distinct Borrelia epitopes, offering high specificity and sensitivity. Designed for research use only (RUO), the kit enables early, strain-specific detection and can be adapted for various laboratory settings, providing enhanced diagnostic accuracy and deeper insights into Lyme disease.

In May 2024, T2 Biosystems Inc., a US-based in vitro diagnostics company, formed a partnership with ECO Laboratory to improve early Lyme disease detection. This collaboration focuses on advancing the development and clinical validation of the T2Lyme Panel, a molecular diagnostic test aimed at providing accurate and early detection of Lyme disease. The partnership utilizes ECO Laboratory’s CLIA-certified facilities to broaden access to advanced tick-borne disease testing throughout the United States. ECO Laboratory is a US-based diagnostic service provider specializing in Lyme and other tick-borne illnesses.

Major players in the lyme disease testing market are Roche Holding AG, Thermo Fisher Scientific Inc., Labcorp Holdings Inc., Quest Diagnostics Incorporated, Eurofins Scientific, BIOMÉRIEUX, Quidel Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., DiaSorin S.p.A, Meridian Bioscience, Everlywell, Trinity Biotech, T2 Biosystems, IGeneX, Viramed Biotech AG, Ceres Nanosciences, Galaxy Diagnostics, Novatein Biosciences, and Lyme Diagnostics Ltd.

North America was the largest region in the lyme disease testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in lyme disease testing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the lyme disease testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The lyme disease testing market includes revenues earned by entities by providing services such as diagnostic test kit development, laboratory testing services, polymerase chain reaction (PCR)-based testing, serological testing, and point-of-care testing solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

The lyme disease testing market research report is one of a series of new reports that provides lyme disease testing market statistics, including lyme disease testing industry global market size, regional shares, competitors with a lyme disease testing market share, detailed lyme disease testing market segments, market trends and opportunities, and any further data you may need to thrive in the lyme disease testing industry. The lyme disease testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Lyme disease testing involves diagnostic methods used to identify infection with Borrelia burgdorferi, the bacterium responsible for Lyme disease, which is commonly transmitted via tick bites. The primary goal of Lyme disease testing is to ensure accurate diagnosis, particularly in individuals presenting symptoms such as fever, fatigue, and the distinctive bull's-eye rash.

The primary types of tests used in Lyme disease diagnostics include serological tests, nucleic acid tests, urine antigen tests, and others. Serological tests detect the presence of antibodies or antigens in a patient's blood to determine exposure to infections or immune responses. Common testing techniques include enzyme-linked immunosorbent assay (ELISA), Western blot, polymerase chain reaction (PCR), immunofluorescence assay (IFA), and others. Testing is applicable across different disease stages, including early Lyme disease, disseminated Lyme disease, chronic Lyme disease, and asymptomatic infection detection. Various sample types used include blood, urine, cerebrospinal fluid (CSF), and more. These diagnostic procedures are carried out by a range of end users, such as hospitals and clinics, diagnostic laboratories, home care settings, research institutions, and public health agencies.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.